The EURJPY pair still affected by the domination of the sideways bias by fluctuating within the sideways track represented by 161.60 support and 163.25 resistance.
Note that stochastic continuous negative momentum might push the price to attack the current support, while breaking it will push the price to form new negative trades to target 160.90 and 160.20 levels.
The expected trading range for today is between 161.65 and 163,25
Trend forecast: Neutral
Under the UK’s Pharmacy First initiative, people are encouraged to see their pharmacist before consulting their GP – especially for minor ailments. It’s a tough four-year course to become a pharmacist in the UK, so you’re in good hands if you seek their advice.
However, on stepping in to any community pharmacy, you might be surprised by the welter of products on sale – from decongestant drugs to homeopathic remedies – that have little or no evidence to support their effectiveness.
For example, oral phenylephrine has been shown to be ineffective as a nasal decongestant. Following a review of the evidence, late last year, the US Food and Drug Administration advised that oral versions of the drug (pills, soluble powders and syrups) should no longer be sold as a treatment for a blocked nose.
Phenylephrine is the main decongestant ingredient in many over-the-counter cold remedies.
Meanwhile, the UK’s Medicines and Healthcare Products Regulatory Agency’s chief safety officer, Alison Cave, said there are “no safety concerns” over phenylephrine products and “people can continue to use as directed”. Although safety is not what’s in question. Effectiveness is.
The flu drug oseltamivir also has little evidence of effectiveness – at least in otherwise healthy people. The UK government, however, still recommends its use in seasonal flu outbreaks.
A recent meta-analysis of 33 clinical trials, with a combined 19,000 patients, showed that oseltamivir, and similar antivirals, might be useful if given to patients who are at a high risk of severe disease. However, they only worked if given within 48 hours of exposure to the flu virus. These drugs had little or no effect on most people who are at low risk or who look for treatments after the 48-hour window.
In 2017, the World Health Organization (WHO) downgraded the status of oseltamivir from “essential” to “complementary”.
The WHO strongly advises against giving oseltamivir to people with “suspected or confirmed non-severe seasonal influenza virus infection”. The drug doesn’t seem to help people at low risk of severe flu and can have unpleasant side-effects.
Of course, pharmacies don’t just sell drugs. They also sell supplements, such as vitamins and minerals, herbal medicines and homeopathic remedies.
Although more than half the UK population takes a multivitamin or dietary supplement, scientists still debate their benefits. A recent large study found that taking a daily multivitamin doesn’t appear to be associated with a mortality benefit.
On the other hand, taking a vitamin D supplement is recommended for those with a deficiency – especially during the dark winter months. Studies have shown that it may reduce the risk of heart attacks and strokes in older people. And people with periods can benefit from vitamin C as it helps with iron absorption.
Medicines in the UK must demonstrate safety, quality and efficacy – but these criteria don’t apply to supplements, herbal medicines and homeopathic products. These products only have to demonstrate safety and quality.
The Royal Pharmaceutical Society states that there is “no evidence from randomised controlled trials for the efficacy of homoeopathy over placebo, and no scientific basis for homoeopathy”. However, it was only as recently as 2017 that the NHS agreed to cease providing homeopathic treatments.
If the evidence says that they don’t work, why do people take these products?
Placebo effects may be part of the reason. The person may believe that the treatment will work and this may lead to them thinking that they feel better. Most of these products are sold for self-limiting conditions and are aimed at helping people feel better while they recover.
Pharmacies have always sold complementary therapies, although these products have changed with the times. You won’t find tonic wine anymore, and there’s much less call for malt extract with cod liver oil.
So why do UK pharmacies sell products with little or no evidence of effectiveness?
Data from Community Pharmacy England suggests that 90% of the income of the average pharmacy comes from the NHS. But, over the last ten years, that funding has seen a 30% real-term cut, even in the face of new services, such as Pharmacy First.
Is it any wonder then that community pharmacies are moving into private services, such as weight loss, and expanding the range of lifestyle products they sell?
Also, many pharmacists work for larger companies and these companies might value profit over evidence-based treatments. Their shops can be crammed with dubious products with high profitability.
This conflict between pharmacies making a profit and providing the best treatment options and advice is not new and is something that Australia struggled with quite recently, leading to calls for pharmacies to drop products that lack evidence.
As long as pharmacies face NHS spending cuts and have to rely on the sale of products that have little or no evidence for their efficacy to remain afloat, the situation is unlikely to change. In the meantime, ask questions about anything you are considering buying. You can be reassured that if a product isn’t right for your condition, your pharmacist will tell you.
The Conversation offered the Royal Pharmaceutical Society the right of reply and Elen Jones, the society’s director for England and Wales wrote:
“Community pharmacies are the ideal place for open conversations with patients to ensure they make informed decisions about their health, including discussing any questions about the evidence of a product’s clinical effectiveness …
“In the case of homeopathy, the RPS is clear that it has no scientific evidence to support its clinical efficacy beyond a placebo effect and does not endorse it as a form of treatment. Pharmacists should advise people considering homeopathic products about their lack of efficacy beyond placebo and also advise that individuals do not stop taking their prescribed medicines when considering using a homeopathic product.
“Offering a variety of products can be an opportunity for patients to access the pharmacy as a ‘gateway to healthcare,’ encouraging them to seek advice for conditions because they trust their pharmacist. Pharmacists play a crucial role in providing evidence-based care daily, guiding patients towards treatments that are safe and clinically effective, with patient care and safety always as the highest priority.”
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Colin Davidson has previously received funding from the NIH (USA) and the European Community for projects related to drug abuse. He is currently a consultant on novel psychoactive substances for the UK Defence Science Technology Labs and is a member of the Advisory Council on the Misuse of Drugs (UK). He was Head of School of Pharmacy & Biomedical Sciences at the University of Central Lancashire from 2017-2023.
Cathryn Brown is a pharmacist and a member of the Royal Pharmaceutical Society. She is currently a member of the Labour party, and regularly donates to Sense about Science.
Ripple’s price could see a surge after the next SEC update – but can this new L2 ICO be a better opportunity right now?
After a quiet trading period for XRP, the popular altcoin saw an 8% increase in the last 24 hours and regained the $3 target.
Right now, most market participants are waiting for the next step in the SEC trial before they buy or sell more XRP tokens. But with the current pro-crypto environment, the future looks optimistic.
At the same time, there’s a new Layer-2 ICO that’s also gaining attention – Solaxy ($SOLX).
With $15.8 million raised in the presale so far and the promise of several robust features, Solaxy might be one of the most interesting projects to watch right now.
Let’s check out all the deets.
XRP is trading at approximately $3.10, maintaining its position above the 50-day and 200-day Exponential Moving Averages (EMAs). It’s up by 8% in the last 24 hours (TradingView).
A move beyond the recent high of $3.20 could pave the way for a rise towards $3.40, potentially challenging the all-time high of $3.55 set in 2018.
However, developments in the ongoing legal case between Ripple and the U.S. Securities and Exchange Commission (SEC) remain a major factor. A key court date is scheduled for April 16, 2025, which could influence XRP’s trajectory.
The SEC’s January 23rd closed meeting, with Commissioner Mark Uyeda as acting Chair, discussed several enforcement cases, including Ripple.
Uyeda’s known preference for reducing non-fraud enforcement actions has sparked interest in the crypto community. While any appeal withdrawal would need a quorum of three Commissioners, recent changes like the withdrawal of SAB 121 suggest possible shifts in SEC policy.
A follow-up meeting on January 30th could provide more clarity on legal settlements and enforcement actions. The outcome could significantly impact XRP’s future, particularly regarding potential spot ETF applications.
If the SEC drops its appeal and approves ETF applications, XRP might surpass its previous peak of $3.55.
Solaxy is a promising solution that could bridge the gap between two major blockchain ecosystems – Solana and Ethereum.
Through its innovative multi-chain application layer, Solaxy can combine Solana’s renowned speed and cost efficiency with Ethereum’s established DeFi infrastructure and security.
At the heart of this integration is the $SOLX token, which can facilitate seamless transactions between both networks.
While Ethereum remains the dominant force in DeFi despite its scaling challenges, and Solana excels in performance but faces interoperability limitations, Solaxy creates a pathway to harness the strengths of both platforms.
The project comes at a crucial time when blockchain interoperability is increasingly vital. Although Ethereum’s proof of stake transition and Layer-2 solutions have brought improvements, the need for efficient cross-chain communication continues to grow.
Solaxy addresses this by enabling developers and users to access both ecosystems’ resources through a unified interface, potentially opening new opportunities for DeFi and cross-chain liquidity.
The crypto community has shown remarkable interest in $SOLX, with its presale raising over $15.9 million despite still being in the early stages.
The project uses a tiered pricing approach, with tokens currently available at $0.001618 – though this price is set to increase soon.
What’s catching attention isn’t just the token itself, but the staking rewards on offer. The current annual percentage yield (APY) stands at an impressive 250%, which explains why nearly 1.6 billion coins have already been staked by early investors.
Adding to the project’s credibility, cryptocurrency analyst ClayBro, known for his accurate market predictions and 130,000-strong subscriber base, has highlighted $SOLX’s potential. His recent analysis suggests the token could be a valuable long-term investment opportunity.
For those considering joining the presale, the current price point offers an entry opportunity before the next scheduled increase. The combination of early success, staking rewards, and expert endorsement has created a lot of excitement around this new project.
Ripple’s XRP price currently hinges on the SEC trial outcome – but the future looks good with the pro-crypto administration now in office.
Meanwhile, new ICOs are also gaining traction. One project that’s been particularly trending is Solaxy ($SOLX), a new Layer-2 solution for Solana’s blockchain.
The presale is coming to an end in the next few weeks, so it might be interesting to keep an eye on its developments.
Early investors can buy and stake $SOLX tokens in the ongoing presale which raised nearly $16 million already.
This article is sponsored content. All information is provided by the sponsor and Brave New Coin (BNC) does not endorse or assume responsibility for the content presented, which is not part of BNC’s editorial. Investing in crypto assets involves significant risk, including the potential loss of principal, and readers are strongly encouraged to conduct their own due diligence before engaging with any company or product mentioned. Brave New Coin disclaims any liability for any damages or losses arising from reliance on the content provided in this article.
Recent shifts in U.S. cryptocurrency policy have significantly impacted Ripple’s XRP, a key player in the crypto market despite incurring over $100 million in legal costs from its SEC battle.
At the same time, PlutoChain, an emerging blockchain platform integrating AI and smart contracts with Bitcoin, is capturing whale attention with its innovative approach. Here’s a closer look at what’s driving these two projects forward.
XRP is trading at $2.78, down 10.5% in 24 hours, 15.9% over the past week, and 28.6% from last month. Key support levels are $2.52 and $2.32, while breaking $3.15 and $3.21 could signal recovery. With an RSI of 24.45, XRP is in oversold territory.
The New York Department of Financial Services (NYDFS) approved Ripple’s stablecoin, RLUSD, boosting its digital payment platform. In Europe, WisdomTree launched the WisdomTree Physical XRP ETP on major exchanges, offering investors affordable XRP access with a 0.50% management fee and secure dual custody.
On the legal front, optimism is growing as President-elect Donald Trump considers crypto-friendly Paul Atkins for SEC leadership, potentially easing Ripple’s legal challenges stemming from the SEC’s 2020 lawsuit.
Armando Pantoja, a prominent crypto analyst on X, predicts that XRP could reach a price range of $8 to $12.
Another analyst, DC, predicts that XRP will surge to $10 and potentially climb even higher, ending the current bull run in the $15-$20 range.
PlutoChain ($PLUTO) has the potential to address Bitcoin’s biggest limitations — slow transaction speeds, high fees, and congestion.
By introducing a hybrid Layer-2 solution, PlutoChain provides a parallel network that could work seamlessly with Bitcoin’s blockchain, ease traffic, and cut costs while dramatically boosting scalability.
Bitcoin’s 10-minute block time has always been a hurdle, especially when compared to faster networks like Solana and Ethereum.
PlutoChain, however, offers a 2-second block time on its own hybrid L2 chain. This could open up Bitcoin to new possibilities, including smart contracts, decentralized finance (DeFi), and even NFTs.
Developers could also migrate Ethereum-based projects onto PlutoChain with ease, thanks to its Ethereum Virtual Machine (EVM) compatibility.
One feature that sets PlutoChain apart is its emphasis on empowering developers. The platform provides user-friendly tools and comprehensive documentation.
This support could encourage developers to explore Bitcoin’s untapped potential, which could lead to the creation of real-world applications that were once out of reach.
PlutoChain’s performance isn’t just theoretical. Its testnet already handles over 43,200 daily transactions without delays or congestion, which proves its scalability.
Security is equally robust. Audits by SolidProof, QuillAudits, and Assure DeFi, coupled with regular stress tests, make sure the network remains secure and reliable.
XRP remains a strong contender, backed by Ripple’s ongoing innovations and improving regulatory outlook. Its potential to reach new heights hinges on DeFi growth and market adoption.
However, for developers and users seeking cutting-edge scalability, PlutoChain ($PLUTO) could be interesting to keep an eye on.
With its lightning-fast block times, EVM compatibility, and robust security, PlutoChain could address Bitcoin’s limitations while potentially opening doors to DeFi, NFTs, and more.
– – –
Please keep in mind that this article is not financial advice. All crypto tokens are volatile, and trading involves risk. Always do your own research and consult a qualified expert before joining any crypto venture. Mention of any tokens in this article does not guarantee future performance. Statements regarding the future carry risks and are not assured to be updated.
Disclosure: This is a sponsored press release. Please do your research before buying any cryptocurrency or investing in any projects. Read the full disclosure here.
Bitcoin price (BTCUSD) trades positively to attempt to breach 102900.00$ level, reinforcing the expectations of continuing the bullish trend for the rest of the day, reminding you that our main waited target reaches 108350.45$.
Stochastic overlaps positively to support the expectations to rise in the upcoming sessions, reminding you that the continuation of the bullish wave depends on the price stability above 100150.00$.
The expected trading range for today is between 100000.00$ support and 106000.00$ resistance.
Trend forecast: Bullish
Ethereum price (ETHUSD) bounced bearishly after testing 3222.00$ level in the previous sessions, to reach the key support 3017.30$, noticing that the price attempts to recover and build new bullish wave, motivated by stochastic current positivity.
Until now, our neutrality still valid until the price confirms surpassing one of the above mentioned levels, noting that breaking the mentioned support will put the price under additional negative pressure that targets 2765.00$ areas on the near-term basis, while breaching the resistance will motivate the price to build new bullish wave that its first main target located at 3425.50$.
The expected trading range for today is between 2970.00$ support and 3260.00$ resistance.
Trend forecast: Neutral
Tea plantations
| Photo Credit: Special Arrangement
A mighty gaur amidst lush green tea gardens and misty hills in the backdrop. This picture postcard frame brings our Jeep to a screeching halt. I take my phone out and click away as the gaur stops and stares before nibbling at the tea leaves. I am thrilled with my encounter with a robust gaur during my Monkey Trails outing, an immersive experience at tea gardens in Hulical, near Coonoor. As we begin the 30-minute drive from Coonoor snaking through tea plantations, beautiful vistas of the Nilgiris landscape unfolds at every corner shrouded in mist.
A mighty gaur at the teas estate in Coonoor
| Photo Credit:
K Jeshi
“We started this to show tourists visiting the Nilgiris that this hill town has so much more to offer beyond the touristy Lambs’ Rock and Dolphin’s Nose,” says Nikhil Suresh, proprietor of Money Trails experiences in Coonoor. Nikhil, along with his brother Nitin Suresh, run a group of hotels and restaurants in Coonoor, including the Realm resort, Hopscotch restobar, Sri Lakshmi Cafe and Hotel Ramachandra. “People visiting here for the second or third time want an offbeat experience. This trail allows them to take it slow with a couple of activities, but is hands-on and immersive,” explains Nikhil.
Elaborating further, he adds Monkey Trails has been curated keeping in mind tourists who halt in Coonoor for a few hours during the Nilgiris trip. “There are weekend travellers. Sometimes they take the train from Ooty and are here in the afternoon to spend a few hours and take the train back. We have kept it short, something that can be done in three to four hours, but memorable.”
Strawberry picking is popular as a great bonding activity for families
| Photo Credit:
Special Arrangement
The first halt is at Velmurugan Tea Plantations in Selas, nine kilometres from Coonoor, for a boutique tea experience. For the first ten minutes, B Lakshman, owner of the tea plantation, teaches us tea culture, history and current trends before taking us on a guided tour of the factory. We witness how hand-picked tea leaves go through various processes before becoming the final product.
The freshly-plucked green leaves undergo withering, rolling, fermenting, and drying, which turns them into black aromatic tea. A cool breeze washes my face, heavy with the aroma of tea leaves. A tea tasting session follows. A cup of invigorating tea that is hot, fresh, and locally produced, makes the experience complete.
Nature walks is a part of the trail
| Photo Credit:
Special Arrangement
The trails can also be customised. There are sunrise walks, guided bird-watching trips with a naturalist, and a herpetology trail with an in-house herpetologist to watch species of frogs and snakes. “We have people calling at 2pm to go for strawberry picking, which is impossible. We can tailor the itinerary based on their expectations when booked in advance. We are working on forest treks. Right now, the hotel fraternity is working with the tourism department and the forest department to explore buffer zones where treks are possible,” he says adding that strawberry picking is most popular as it’s a great bonding activity for families.
Strawberry farms
| Photo Credit:
Special Arrangement
Guests take a leisurely stroll through rows of lush strawberry plants and hand-pick the ripest, juiciest strawberries directly from the farm, grown without pesticides. “They start planting in November after the rains and the crops are ready by February. There will be crops remaining till September. While controlled environment has crops through the year, this is a natural open farm and the hands-on experience is a great way for adults and children to connect with Nature,” explains Nikhil.
Boutique experience at the tea factory
| Photo Credit:
Special Arrangement
For weekend travellers, there are small combo trails that pack Jeep rides, plantation walk, tea tasting and strawberry picking. We bite into crisp Ooty varki and enjoy refreshing lemon tea at Realm resort while soaking up views of farms resembling white specks from a distance. Those are blueberry farms being developed now, we are told, as we hop on to the Jeep to visit a stream nearby. As we dip our feet in pristine, icy cold waters of the stream, there is absolute silence punctuated by the chirping of birds. We enjoy the bite of the mountain air as we begin the drive back filled with happy moments.
Booking for the Monkey Trails experiences has to be done in advance. For more details, call 9585316161/ 9787317171
Published – January 29, 2025 04:30 pm IST
Crypto investors are looking for the next big opportunity as the market enters a new bull run. Currently, Solana, Injective Protocol (INJ) and Remittix (RTX) are at the forefront of attention and are expected to see huge returns.
Here’s why experts believe these three projects could lead the market in 2025.
Delays and technical issues have long hindered international transactions. These challenges disrupt businesses, inconvenience individuals, and prevent impoverished populations from accessing global financial systems.
Remittix (RTX) has introduced a revolutionary protocol to solve these problems and set a new benchmark for global payments. Through the platform users can send funds directly to banks globally, with Remittix transforming over 40 cryptocurrencies into fiat currencies. Transactions are completed in less than 24 hours, saving time for traders, freelancers, and companies that need fast cash flow.
Transparency and privacy are essential values of Remittix. Through a flat-rate pricing model, the platform provides transparent and predictable costs without hidden fees. Recipients receive money as standard bank transfers and are not identified as cryptocurrencies—protecting privacy for users.
Businesses can also benefit from Remittix. The Remittix Pay API allows companies to accept and settle crypto payments in fiat. With support for over 30 FIAT currencies and over 50 cryptocurrency pairs, businesses, freelancers, and e-commerce platforms can operate seamlessly across global markets.
Remittix prioritizes financial inclusion by targeting underserved regions. The platform operates 24/7 and offers access to global financial systems without relying on traditional banking infrastructure.
The platform is powered by its RTX token which is currently priced at just $0.0418. With over 400 million RTX tokens sold and over $8.5 million raised, analysts predict a 100x surge before the token lists on exchanges.
Solana (SOL) is among the most famous Layer-1 blockchains. Solana trades today for $233.61, down 7.41% over last week’s value. Despite this decline, Solana’s 4-hour chart shows a symmetrical triangle pattern formation, indicating a breakout.
Currently, SOL is supported by an ascending trendline and the 50 SMA, trading just under $238.61. As the price narrows between upward and downward trendlines, analysts expect a breakout that could push Solana toward resistance levels at $271 and $295, offering a 13% potential price increase. Additionally, the MACD indicator shows bullish momentum, suggesting a possible upward trajectory.
Injective dropped 16% over the last week, taking its price to $18. The coin had recently surged to $26 but faced intense selling pressure as holders cashed in on the rally’s profits. The 24-hour trading volume has increased by 137%, with over $181 million worth of Injective tokens traded on exchanges.
Injective recently partnered with io.net, allowing AI agents to send payments and make trades on-chain through AI-generated commands. io.net contributes a network of 10,000 GPUs and CPUs, which could solidify Injective’s position in DeFi and push its price to $100 this quarter.
Market experts are backing Solana, Injective, and Remittix for 100x gains this year. Of the three, Remittix takes the lead as the potential winner. The Remittix presale offers early buyers the opportunity to purchase RTX tokens for just $0.0456. With over $9 million raised already, experts forecast an 800% surge in value by the end of the presale. After launch, a potential 5,000% rally is also predicted, making it a steal for early adopters.
Join the Remittix (RTX) Community
Gold price clings to recovery gains near $2,770 in Wednesday’s Asian trading. Gold buyers trade cautiously, heading into the critical Federal Reserve (Fed) policy announcement that is due later this Wednesday.
Markets are in a wait-and-see mode, anticipating the Fed will pause the interest rate cut and provide hints on the following policy move. Markets are pricing in almost 50 basis points (bps) of cuts this year, or two 25 bp reductions starting in June, according to LSEG data.
However, Fed Chairman Jerome Powell’s press conference will be closely scrutinized for the timing and the scope of further rate reductions under US President Donald Trump’s second term. Trump’s immigration and trade policies are perceived as inflationary, as they could prompt the Fed to keep higher rates for longer, boding ill for the non-interest-bearing Gold price.
In case, Powell and his colleagues express their confidence in the path of disinflation and acknowledge weakening labor market conditions, markets could read that as a dovish hold, ramping up bets for future rate cuts, lifting Gold price to new record highs.
In the meantime, Gold price will continue to draw support from stabilizing risk sentiment, broadly subdued US Dollar and holiday-thinned conditions. China, Singapore, and Hong Kong markets also closed due to the Lunar New Year holiday break.
Markets recover from China’s low-cost artificial intelligence (AI) model – DeepSeek-led global AI sell-off as the focus now also remains on the earnings results from the US tech titans – Microsoft, Meta and Tesla due in the late American session on Wednesday.
If earnings disappoint and budget forecasts leave investors unconvinced, a renewed global tech sell-off could be in the offing, with markets resorting to ‘sell-everything’ mode. In such a case, Gold price could reverse any reaction to the Fed policy announcements or extend the downside on a potential hawkish hold.
The technical setup on the daily time frame remains in favor of Gold price. Therefore, the bright metal will likely be a ‘buy-the-dips’ trade.
The 14-day Relative Strength Index (RSI) holds comfortably above the midline, currently near 65, keeping Gold buyers hopeful.
Adding credence to the bullish potential, the 50-day SMA closed above the 100-day SMA last Thursday, confirming a Bull Cross.
Gold price needs a daily candlestick closing above the symmetrical triangle target of $2,785 or record high of $2,790 to initiate a fresh uptrend.
The next relevant upside targets are $2,800 and the $2,850 psychological barrier.
On the downside, the immediate support will be seen at the previous day’s low of $2,735.
Sellers will then aim for the $2,700 round level, where the 21-day SMA coincides. The last line of defense for buyers is the $2,680 static support.
Monetary policy in the US is shaped by the Federal Reserve (Fed). The Fed has two mandates: to achieve price stability and foster full employment. Its primary tool to achieve these goals is by adjusting interest rates. When prices are rising too quickly and inflation is above the Fed’s 2% target, it raises interest rates, increasing borrowing costs throughout the economy. This results in a stronger US Dollar (USD) as it makes the US a more attractive place for international investors to park their money. When inflation falls below 2% or the Unemployment Rate is too high, the Fed may lower interest rates to encourage borrowing, which weighs on the Greenback.
The Federal Reserve (Fed) holds eight policy meetings a year, where the Federal Open Market Committee (FOMC) assesses economic conditions and makes monetary policy decisions. The FOMC is attended by twelve Fed officials – the seven members of the Board of Governors, the president of the Federal Reserve Bank of New York, and four of the remaining eleven regional Reserve Bank presidents, who serve one-year terms on a rotating basis.
In extreme situations, the Federal Reserve may resort to a policy named Quantitative Easing (QE). QE is the process by which the Fed substantially increases the flow of credit in a stuck financial system. It is a non-standard policy measure used during crises or when inflation is extremely low. It was the Fed’s weapon of choice during the Great Financial Crisis in 2008. It involves the Fed printing more Dollars and using them to buy high grade bonds from financial institutions. QE usually weakens the US Dollar.
Quantitative tightening (QT) is the reverse process of QE, whereby the Federal Reserve stops buying bonds from financial institutions and does not reinvest the principal from the bonds it holds maturing, to purchase new bonds. It is usually positive for the value of the US Dollar.
Platinum price repeated the negative closings below 955.00$ barrier, hinting its surrender to the continuous domination of the correctional bearish bias by consolidating near 940.00$.
Also, stochastic continuous negative momentum assists to provide more negative trades until reaching the additional support at 920.00$, while breaching the barrier and holding above it will push the price back to the bullish track to expect achieving many gains by rallying towards 972.00$ followed by reaching 983.00$.
The expected trading range for today is between 920.00$ and 955.00$
Trend forecast: Bearish
